

Centrale Commissie Mensgebonden
Parnassusplein 5
2511 VX Den Haag

25 January 2024

Subject: Clinic
A Phase 1
Protocol title: Efficacy and Safety of the
Deciphering of the
Advancing of the
EDO-1002
2020
Protocol number: NL75
EudraCT number: 2020
ToetsingOnline number: Mun
Sponsor: Mun

Dear reader,

On behalf of the Sponsor, Mundi
results for the EDO-S101-1002 clinical

Please note, result summaries have
Phase 1 was completed in the US

Please find below the list of documents

- EDO-s101-1002_CCMO_C
- CSR Phase 1 synopsis_EDC
- CSR Phase 2 and sub studies

If you have questions, please do not
forward to hearing from you at your

Sincerely, *Merel Woldk*
on behalf of

Cinzia Bernini | Head of Clinical Choice
CROMSOURCE S.r.l. (a ClinChoice)
Email: Cinzia.Bernini@clinchoice.

Study, Pharmacokinetics and
Class Alkylating Histone
Molecule, in Patients with

and enclosed a summary of

Phase 2 of this clinical trial,

Location:

cover letter)

2

ion 1_18dec2022 3

*certification
M. Woldk
06 feb 24*

information. We are looking